Since total knee arthroplasty (TKA) is considered a high risk factor for venous thromboembolism (VTE), thromboprophylaxis is commonly recommended 1) . However, the actual incidence of VTE and the need for routine thromboprophylaxis after TKA in Asians are controversial. A recent metaanalysis showed that the incidences of deep vein thrombosis (DVT) and symptomatic pul monary embolism (PE) were low (40.4% and 0.01%, respectively) in Asians without chemoprophylaxis, despite the westernized life style and aging of the population 2) . However, since the incidence of DVT proven by venography is reported to be 50%-76.5% and that of PE proven by lung perfusion scan is 17.1% in cases with out prophylaxis, routine thromboprophylaxis should be reconsid ered 3, 4) . In contrast to Western studies, which typically describe the incidence of VTE with chemoprophylaxis, most Asian re ports have investigated the incidence without chemoprophylaxis. Thus, due to insufficient data, the need for prophylaxis after TKA in Asians remains debatable.
Introduction
Since total knee arthroplasty (TKA) is considered a high risk factor for venous thromboembolism (VTE), thromboprophylaxis is commonly recommended 1) . However, the actual incidence of VTE and the need for routine thromboprophylaxis after TKA in Asians are controversial. A recent metaanalysis showed that the incidences of deep vein thrombosis (DVT) and symptomatic pul monary embolism (PE) were low (40.4% and 0.01%, respectively) in Asians without chemoprophylaxis, despite the westernized life style and aging of the population 2) . However, since the incidence of DVT proven by venography is reported to be 50%-76.5% and that of PE proven by lung perfusion scan is 17.1% in cases with out prophylaxis, routine thromboprophylaxis should be reconsid ered 3, 4) . In contrast to Western studies, which typically describe the incidence of VTE with chemoprophylaxis, most Asian re ports have investigated the incidence without chemoprophylaxis. Thus, due to insufficient data, the need for prophylaxis after TKA in Asians remains debatable.
Chung et al. Rivaroxaban and Acetylsalicylic Acid for Prevention of VTE Following TKA in Koreans
results compared with lowmolecularweight heparin (LMWH) 5) . However, there has been no report on the VTE incidence after TKA with chemoprophylaxis using rivaroxaban or acetylsalicylic acid (AA) in Asian patients. Traditionally, the VTE prevalence is believed to be lower in Asians than in Caucasians 6) , and recent reports confirmed this belief 2) , and shorter prophylactic regimens tend to be favored in Asian patients; however, no supporting evi dence has been found thus far.
In the present study, we investigated the actual incidence of VTE and hemorrhagic outcome after TKA with currently avail able chemical thromboprophylaxis in Korean individuals. We also studied whether a shorter prophylactic duration has a similar prophylactic effect compared with the currently recommended duration in Korean patients.
Materials and Methods
The protocol was approved by the Institutional Review Board (HYUH IRB no. 2011R37), and all patients provided informed consent. The inclusion criteria for this prospective, randomized and controlled study were patients who underwent primary TKA, including unilateral or staged bilateral TKA with a 2week interval, between May 2011 and November 2013. A total of 278 patients (341 cases) who met the inclusion criteria were allocated into 3 groups according to the different prophylactic regimens.
We assessed the patients for VTE using a 64channel multide tectorrow computed tomography (MDCT) indirect venography system (Brilliance 64; Philips, Eindhoven, The Netherlands) at 10 days postoperatively. The exclusion criteria included renal insuf ficiency, contrast allergy, simultaneous bilateral TKA, MDCT conducted before 10 days postoperatively due to suspicious VTE symptoms 7, 8) , a previous VTE history and varicose veins. After applying the exclusion criteria, 268 patients were ultimately included in the study with 110 cases allocated in each group ac cording to the computergenerated randomization code (Fig.  1 ). In the cases of staged bilateral TKA, the same prophylactic regimen was used for the first and second operations. Baseline demographics and clinical characteristics including Charlson co morbidity index were similar among 3 groups (Table 1 ).
Thromboprophylactic Regimens
Patients were randomly allocated into 3 groups according to the different prophylactic regimens. In group A (90 patients, 110 cases), subcutaneous injection of 5,000 international units (IU) of Fragmin (dalteparin, LMWH; Pfizer, New York, USA) was given daily for 2 postoperative days, which was followed by 5 days of 100 mg aspirin (AA; Bayer, Leverkusen, Germany) therapy. In group X7 (92 patients, 110 cases), a shorter regimen of 10 mg Xarelto (rivaroxaban, factor Xainhibitor, Bayer) was given orally for 7 days postoperatively. In group X10 (86 patients, 110 cases), 10 mg Xarelto was given orally for 10 days postoperatively. Pro phylaxis was started at 6 hours after the end of surgery. For all patients, intermittent pneumatic compression was applied imme diately after surgery and maintained for 7 days. However, a com pression stocking was not applied. A continuous passive motion machine was used at 1 day postoperatively. Fisher exact test.
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Evaluation of VTE
We assessed the occurrence of a VTE event using MDCT at 10 days postoperatively. Six seconds after the signal density level reached 100 hounsfield units (HU), a computed tomography (CT) scan was performed from the costophrenic angle to the lung apex. After the injection of contrast media (Ultravist 370, Iopromide, Bayer) thorough the antecubital vein, indirect ve nography was performed to obtain contrastenhanced venous phase images. Based on the literature, the estimated radiation dose received per MDCT scan of this study is approximately 7 mSv for PE scan and 8 mSv for DVT scan 9, 10) . A single radiologist evaluated the CT images in a blinded manner. Symptomatic PE was defined as PE with additional symptoms, such as dyspnea, pleuritic chest pain, cough, hemoptysis, tachypnea, rales, or tachycardia 7) . Symptomatic DVT was defined as DVT involving discomfort of the calf or thigh, a Homan's sign, swelling, localized hotness, skin discoloration, tenderness, or prominence of the superficial veins 8) . If the patient presented with severe symptoms, we performed MDCT before 10 days postoperatively. The VTE cases were divided into PE and DVT, and the latter was further subcategorized into proximal DVT (occurring in the popliteal vein and above) and distal DVT (occurring below the popliteal vein).
If a patient had asymptomatic distal DVT, the patient was only observed conservatively without any treatment. We only treated patients with PE, symptomatic DVT, or proximal DVT, and a pulmonologist or a chest surgeon was consulted for the manage ment of these patients with anticoagulants. At 3 months post operatively, patients who had VTE events underwent followup MDCT to evaluate the change in VTE.
Evaluation of Hemorrhagic Outcome
The bleeding amount was checked by drain removed routinely after 48 hours. Bleeding events were classified as major or minor. Major bleeding comprised intracranial, intraocular, retroperi toneal, intraspinal or pericardial bleeding 11) . Minor bleeding in cluded any unexpected hematoma (>25 cm 2 ), threatened wound hematoma, nasal, gingival, rectal or vaginal bleeding, macroscop ic hematuria, coughing or vomiting blood 12) . Transfusion volume was compared among groups. Additionally, the transfusion volume of staged bilateral TKA patients was compared to that of unilateral TKA patients in each group.
Statistical Analysis
The sample size and power calculation was based on the ex pected incidence of VTE that was approximately 50% 13) in group A, 20% 14) in group X7, and 7% 12) in group X10. The minimal expected difference in VTE incidence was noted between groups X7 and X10, which was 13%. Statistical significance was set at 5% (p<0.05) with a power of 80%; thus, the minimum sample size for each group was set as 110 cases by the chisquare test, consid ering a dropout rate of 10%. Statistical analysis was performed with SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA). For compari son of the categorical and proportional variables, the Chisquare test was used. If more than 20% of the expected frequencies were less than 5, the Fisher exact test was performed. Oneway analysis of variance was used to compare the results of numerical con tinuous variables. However, for some variables without normal distribution, the KruskalWallis test was used.
Results
The incidence of VTE is described in Table 2 . Compared to group A, the incidence was significantly lower in groups X7 and X10. The incidence was significantly lower in group X10 than that in group X7 (p=0.038). Group X10 had a significantly lower incidence compared with groups A and X7 in terms of PE and PE plus proximal DVT plus symptomatic DVT. In contrast, no significant differences were observed between groups A and X7 (p=0.056 and p=0.074, respectively). The incidences of proximal DVT and symptomatic DVT were similar among the 3 groups, and symptomatic PE was not observed in any of the groups. All DVT events occurred on the operated side.
The results of followup MDCT are summarized in Table 3 . In the cases of asymptomatic distal DVT only, 24/27 (88.8%) dem onstrated complete resolution, whereas the remaining 3 cases showed a reduced amount of thrombosis without symptoms. All the proximal and symptomatic DVT cases resolved completely, except for 4 patients who refused to take followup MDCT with out suspicious VTE symptoms. In cases of PE, 96.7% showed complete resolution (29/30); only 1 patient, in group X7, did not show resolution of PE, which then progressed to chronic PE. However, complete resolution of this patient's PE was confirmed by followup MDCT after 6 months of anticoagulation therapy.
The mean bleeding amount was similar among the 3 groups (692 mL in group A, 705 mL in group X7, and 700 mL in group X10; p=0.889) and there was no observable major or minor bleeding event. The transfusion volume was similar among 3 groups (908 mL in group A, 1,014 mL in group X7, and 1,062 mL in group X10; p=0.072). The transfusion volume of staged bilateral TKA patients (909 mL in group A, 1,011 mL in group X7, and 1,067 mL in group X10) was similar to that of unilateral 1.000 Fisher exact test. 
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TKA patients (906 mL in group A, p=0.972; 1,021 mL in group X7, p=0.937; and 1,058 mL in group X10, p=0.920). In addition, in the cases that were excluded from the comparison because the MDCT was performed before 10 days postoperatively, no VTE event was noted.
Discussion
In the present study, we noted that rivaroxaban was more ef fective in lowering the incidence of VTE than AA and that the 10day course of rivaroxaban was more effective than the 7day course. Specifically, compared with AA, the absolute risk reduc tion for VTE, DVT, and PE with 7day rivaroxaban was 18.2%, 20% and 9.1%, respectively; the absolute risk reduction for VTE, DVT, and PE with 10day rivaroxaban was 26.8%, 29.1%, and 16.4%, respectively. Although the 7day rivaroxaban regimen resulted in reduction in the incidence of VTE and DVT events, there was no significant difference in the PE incidence compared with the AA therapy. However, the 10day rivaroxaban regimen significantly reduced the incidence of PE as well as VTE and DVT. Furthermore, no cases of proximal or symptomatic DVT were noted following prophylaxis with a 10day regimen of ri varoxaban. Compared with the 7day rivaroxaban regimen, the absolute risk reduction for VTE and PE with 10day rivaroxaban was 10% and 7.3%, respectively. Thus, the 10day rivaroxaban regimen yielded a significantly superior reduction compared with the 7day rivaroxaban regimen in the incidence of PE plus proxi mal DVT plus symptomatic DVT, the three clinically important events.
At present, no definite strategy for thromboprophylaxis has been established in view of the American Academy of Ortho paedic Surgeons or the American College of Chest Physicians (ACCP) 15, 16) . In the present study, the prophylactic regimens were determined by considering several factors. First, the aver age body weight of Korean patients (60 kg in this study) is lower than that of Caucasians (79 kg) 17) . Second, all patients received concomitant mechanical prophylaxis. Third, Asians have cer tain genetic factors that are associated with a lower prevalence of thrombi 6) . Fourth, we considered some evidence that shows a favorable symptomatic VTE incidence without chemoprophy laxis in Asians 2) . Thus, the prophylactic duration in the present study was set at 10 days, which is the minimal duration recom mended by the ACCP 16) , and the shorter duration of 7 days was set based on the fact that VTE most frequently occurs 5 to 7 days postoperatively 18) . The recommended rivaroxaban dose, 10 mg 12) , was the lowest dose available in tablet form. The comparative group received LMWH plus AA instead of no prophylaxis due to the ethical concern of withholding prophylaxis from patients. LMWH was initially used to enhance the prophylactic effect con sidering the increased VTE risk during the immediate postop erative period based on Virchow's triad (including venous stasis, endothelial injury, and hypercoagulability) and due to the nature of the procedure and/or the high flexion position during TKA 18) . Therefore, we used a regimen involving 2 days of LMWH and 5 days of AA, which has shown satisfactory results in terms of the reduction in symptomatic VTE incidence 19) . This is one of limita tions of this study: we used 100 mg due to the easy availability of the tablet form and the lower body mass of Korean patients.
The ACCP has recently approved the use of AA as a prophy lactic treatment 16) , and 100 mg of AA has shown favorable effects with regard to reduction in the incidence of symptomatic VTE 19) . However, in this study, AA did not seem to be effective: the inci dences of VTE, PE, proximal DVT, and symptomatic DVT with AA were similar to those of another study without prophylaxis in Korean patients (35.7%, 13.5%, 8.7%, and 3.2%, respectively) 20) . In terms of asymptomatic distal DVT, 24/27 (88.8%) of the cases with asymptomatic distal DVT showed complete resolution, and the remaining 3 cases showed significant improvements, with no complications. Moreover, patients who did not undergo follow up MDCT had no suspicious DVT symptoms. Thus, in cases of asymptomatic distal DVT, observation without any specific treat ment may be sufficient.
The need for thromboprophylaxis after TKA in Asians is still debatable. It is important to note that VTE should be considered as a "preventable disease". Surgeons should be aware that more than 90% of PEs develop as a result of lower extremity thrombi 21) , asymptomatic DVT can cause the postthrombotic syndrome, and PE can cause chronic thromboembolic pulmonary hyperten sion 22) . Moreover, surgeons have legal and ethical concerns over what can be considered "preventable". Although current guide lines focus on symptomatic events 23) , symptomatic VTE cannot be selectively prevented.
The present study had several potential strengths. First, this was the first report of VTE incidence after TKA in Korean patients on the recommended or shorter duration of prophylactic therapy. Second, this study assessed VTE events via MDCT that is consid ered the best modality for detecting PE and DVT 24) . However, this study has several limitations. First, the preopera tive VTE status could not be monitored. However, chronic VTE can be detected on MDCT performed to evaluate the formation of thrombi 25) , and no chronic case of VTE was observed. Second, MDCT was performed at 10 days postoperatively; thus, we could Knee Surg Relat Res, Vol. 30, No. 3, Sep. 2018 253 not confirm whether VTE occurred afterwards. However, none of the patients showed any symptoms or signs of VTE during followup at 4-6 weeks and 3 months postoperatively in the out patient department. Third, there was concern regarding radiation exposure with MDCT scans; however, the estimated radiation dose did not exceed the diagnostic reference level of radiation 26) . Fourth, the incidence of VTE was evaluated only among different chemoprophylaxis regimens. However, to determine the need for chemoprophylaxis, the incidence of VTE following mechanical prophylaxis should be evaluated and compared to that follow ing chemoprophylaxis. A welldesigned comparative study of chemoprophylaxis and placebo is needed to establish guidelines for the Asian patients with TKA. Lastly, the inclusion of patients with staged bilateral TKA performed within 2 weeks might have affected the outcomes although only patients without VTE by MDCT at the 1st stage TKA were included.
Conclusions
Rivaroxaban had a lower incidence of overall VTE than AA, but no difference was observed in symptomatic VTE. The 10day course of rivaroxaban had a lower incidence of overall VTE than the 7day course.
